OHAMR Call for proposals 2026

General Information

• Project title: Next-Generation Theranostic Inhalable Therapies Targeting Fungal Infection and Host Immunity
• Type: Project looking for partner
• Organisation: Jagiellonian University Medical College
• Country: Poland (PL)
• Career stage: Early Career Researcher (up to 8 years** since PhD).

Research area

• Scientific area(s) of the call:
  1. Topic 1: Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
• One Health Setting:

  H - Human Health

• Keywords:

  lung aspergillosis; theranostics; immunomodulation; antifungal therapy; inhalation delivery

• Brief description of your expertise / expertise you are looking for:

  Our team has extensive experience in the development of dry powder for inhalation formulations containing antimicrobial agents, as well as in the comprehensive evaluation of inhalable formulations, including biological studies focused on safety and preclinical efficacy in the context of pulmonary delivery and preclinical studies relevant to pulmonary delivery. We have also developed inhalable theranostic formulations for magnetic resonance imaging (MRI). We are seeking collaboration with partners experienced in: (1) investigation of immunological responses, particularly in the context of pulmonary infections (especially. neutrophil chemotaxis); (2) microbiological assessment of the efficacy of powder-based formulations against Aspergillus fumigatus strains; (3) synthesis and characterization of particles with immunomodulatory properties.

• Brief description of your project / the project you would like to join:

  The aim of the project is to develop an inhalable theranostic formulation combining antifungal drugs with agents that stimulate neutrophil chemotaxis for the treatment of pulmonary aspergillosis. In addition, the project will focus on the development and implementation of advanced biological and microbiological models to evaluate the efficacy, immunological impact, and pulmonary performance of the inhaled formulation against Aspergillus fumigatus. Readouts will include cell viability, metabolic activity, gene expression profiling, barrier integrity (TEER), and permeability assays. The theranostic component will enable non-invasive monitoring of drug deposition and distribution in the lungs using magnetic resonance imaging (MRI).

Gabriela Wyszogrodzka-Gaweł

• Organisation: Jagiellonian University Medical College
• Position: PI
• E-mail: gabriela.wyszogrodzka@uj.edu.pl